Thursday, July 29TRUSTED FEARLESS INTERNATIONAL & NATIONAL NEWS PORTAL

Tag: Bharat Biotech

Bharat Biotech terminates pact with Brazil partners Precisa Medicamentos, Envixia Pharma | India News – Times of India
Politics

Bharat Biotech terminates pact with Brazil partners Precisa Medicamentos, Envixia Pharma | India News – Times of India

HYDERABAD: Bharat Biotech, the developer of indigenous Covid-19 vaccine Covaxin, on Friday said it has terminated, with immediate effect, its MoU dated November 24, 2020, with its Brazilian partners for Covaxin — Precisa Medicamantos and Envixia Pharmaceuticals LLC. The move comes days after Brazil suspended its $324 million contract for procuring 20 million doses of Covaxin. While Bharat Biotech did not elaborate on the reasons for terminating the MoU, it said: “We have very recently been informed that certain letters, purported to have been executed by executives of the company, are being circulated online. We would like to emphatically state that these documents have not been issued by the company or its executives and therefore vehemently deny the same.” “The company also stresses t...
Zydus’ vaccine for kids above 12 to come up for approval this week | India News – Times of India
Politics

Zydus’ vaccine for kids above 12 to come up for approval this week | India News – Times of India

NEW DELHI: India’s drug regulator will this week consider emergency use approval for Covid-19 vaccines developed by Zydus Cadila for children above 12. The regulator’s subject expert committee (SEC) will examine data submitted by Cadila. The vaccine has been tested on adults as well as children above 12 and if the regulatory committee is satisfied with the submitted data and documents, the vaccine will be approved for emergency use soon, officials said. An approval can hasten the opening of schools although vaccine supply will remain a concern. “The preliminary assessment of the application submitted by the company is going on and we have sent it to the SEC for further consideration. The SEC will be meeting in the coming week, representatives of the company will be also asked to make pr...
Covaxin Closer To WHO Approval? Covid-19 Vaccine Trial Data ‘Looks Good’, Says Chief Scientist
Politics

Covaxin Closer To WHO Approval? Covid-19 Vaccine Trial Data ‘Looks Good’, Says Chief Scientist

New Delhi: The much-awaited approval for indigenous jab Covaxin developed by Hyderabad-based manufacturer Bharat Biotech from World Health Organisation seems to be closer as the final phase trial data of the vaccine is under study.According to chief scientist at WHO Soumya Swaminathan, who spoke to the channel CNBC TV-18 has indicated that the final phase trial data for Covaxin “looks good” and meets the safety profile of the international public health agency so far.ALSO READ: Now Zika Virus Poses Threat In Kerala, Multiple Cases Detected Amid Covid Second WaveThe pre-submission meeting between Bharat Biotech and WHO was held on June 23, Swaminathan informed the channel saying that the data packet is currently being assembled. Even as the Covaxin's efficacy against ...
Coronavirus Live: Agra Reports Zero Covid Cases After Over 100 Days
Politics

Coronavirus Live: Agra Reports Zero Covid Cases After Over 100 Days

Even as Karnataka readies to further unlock the economy by easing Covid restrictions in the state, including in Bengaluru, lockdown has been extended for two more weeks till July 19 from Monday in Kodagu district, an official said on Sunday."As the positivity rate continues to be at 7.21 per cent, the state government has extended the lockdown in the district by another two weeks to reduce Covid cases below 5 per cent," the district official told IANS on phone.Kodagu is about 240 kms southwest of Bengaluru in the state, nestled in the biodiversity-rich Western Ghats."Along with weekend curfew from 9 p.m. on Friday to 6 a.m. on Monday, night curfew will continue from 9 p.m. to 6 a.m. on all weekdays," said the official.According to the state health bulletin, 182 new cases were registered...
Coronavirus HIGHLIGHTS: Goa Govt Allows Bars, Restaurants To Function With 50% Seating Capacity
Politics

Coronavirus HIGHLIGHTS: Goa Govt Allows Bars, Restaurants To Function With 50% Seating Capacity

Punjab recorded 172 fresh COVID-19 cases and 16 more fatalities on Saturday, taking the state's infection tally to 5,96,265 and the death toll to 16,103, according to a medical bulletin.The number of active cases stand at 2,538 in the state.The fresh deaths due to the disease were reported from several districts, including Amritsar, Bathinda, Fazilka and Ferozepur.Out of the new cases, Ludhiana reported 26 infections, followed by 24 in Jalandhar and 15 in Patiala, among others.The state's positivity rate stands at 0.39 per cent.With 368 more recoveries, the number of cured people reached 5,77,624, the bulletin said.There are 101 critical patients who are on ventilator support, 320 other critical patients and 1,457 are on oxygen support, it said.A total of 1,10,40,759 samples have been c...
Bharat Biotech: Covaxin is 77.8% effective, provides 65.2% protection against Delta variant | India News – Times of India
Politics

Bharat Biotech: Covaxin is 77.8% effective, provides 65.2% protection against Delta variant | India News – Times of India

NEW DELHI: Phase-III trials of Covaxin, made by Hyderabad's Bharat Biotech, showed it was 93.4% effective against severe symptomatic Covid-19, the firm claimed on Saturday. The data demonstrated 65.2% protection against the Delta variant, first identified in India. The Delta variant had led to a surge in infections in April and May, and the world's highest daily death tolls. It further showed effectiveness of 77.8% against symptomatic Covid-19 in the trial. On Saturday, India reported 44, 111 new Covid cases and 738 deaths. The recovery rate further jumped to 97.06% with 2,96,05,779 recoveries. Last month, vaccine maker AstraZeneca also said its vaccine was effective against the Delta and Kappa variants, citing a study. India has been administering the AstraZeneca vaccine, made domestic...
Bharat Biotech’s Covaxin Found To Be 77.8% Effective In Final Analyis Of Phase III Trials
Politics

Bharat Biotech’s Covaxin Found To Be 77.8% Effective In Final Analyis Of Phase III Trials

Hyderabad: Bharat Biotech, the biotechnology firm on Saturday announced the efficacy and safety of the indigenous vaccine Covaxin which was jointly developed with the ICMR & NIV Pune. The firm said that it has concluded the final analysis of the Phase III trials. "Phase 3 clinical trials of Covaxin was an event-driven analysis of 130 symptomatic COVID-19 cases, reported at least two weeks after the 2nd dose, conducted at 25 sites across India," the official press release said. ALSO READ: 'Kangana Suppressed Facts To Get Favorable Order', Javed Akhtar Tells HC Over Copyright CaseKey findings of the analysis:77.8% effective against symptomatic Covid-19, through evaluation of 130 confirmed cases, with 24 observed in the vaccine group versus 106 in the placebo group....
Coronavirus Live: Delhi Markets Shut For Flouting Covid Norms Allowed To Reopen From Today
Politics

Coronavirus Live: Delhi Markets Shut For Flouting Covid Norms Allowed To Reopen From Today

Coronavirus LIVE, Saturday, July 3: Bharat Biotech Concludes Final Analysis for Covaxin Efficacy from Phase 3 Clinical Trials. Efficacy analysis demonstrates Covaxin️ to be 77.8% effective against symptomatic COVID-19, through evaluation of 130 confirmed cases, with 24 observed in the vaccine group versus 106 in the placebo group  Andhra Pradesh on Friday logged 3,464 new Covid cases, pushing the state's overall tally beyond 18.9 lakh, even as its active caseload dropped to 37,323 from 38,178 a day before.As many as 4,284 persons recovered from the disease in the past 24 hours, raising the state's total number of recoveries to over 18.4 lakh.East Godavari district reported the highest number of cases at 667, followed by Chittoor (597), West Godavari (397), Prakasam (349), Nellore...
Covaxin Effectively Neutralises Covid-19’s Alpha & Delta Variant: US Health Research Institute
Business

Covaxin Effectively Neutralises Covid-19’s Alpha & Delta Variant: US Health Research Institute

The United States National Institute of Health (NIH) has said India’s Covid-19 vaccine Covaxin effectively neutralises both Alpha and Delta variants of coronavirus.The results of two studies of blood serum from the people, who had received Covaxin, suggest the vaccine generates antibodies that effectively neutralise the B.1.1.7 (Alpha) and B.1.617 (Delta) variants of SARS-CoV-2, first identified in the UK and India respectively, said the NIH.The NIH, which has a strong scientific collaboration with India, said that an adjuvant developed with funding from it has contributed to the success of the highly efficacious Covaxin.The NIH said Covaxin - developed by Hyderabad-based pharmaceutical company Bharat Biotech in collaboration with the Indian Council of Medical Resear...
Brazil Govt Faces Probe For Choosing Bharat Biotech’s Covaxin Over ‘Cheaper’ Pfizer Vaccine
Politics

Brazil Govt Faces Probe For Choosing Bharat Biotech’s Covaxin Over ‘Cheaper’ Pfizer Vaccine

New Delhi: Congressman Luis Miranda and his brother Luis Ricardo Miranda, who raised suspicions about Brazil's vaccine deal with India's Bharat Biotech, arrived at a Senate commission inquiry on Friday wearing a bullet-proof vest for safety.They are key witnesses in the hearing over alleged wrongdoing in a vaccine contract signed by Brazil's government to procure Covaxin doses in a deal costing1.6 billion reais (USD 323 million).The parliamentary inquiry is looking into the allegations that the Brazilian government deliberately delayed securing Covid vaccines besides the probe on its handling of the coronavirus pandemic that has killed more than half a million people in the country.ALSO READ | US Confirms Wuhan Coronavirus Sequences Removed From Database At Request O...
Bolsonaro says Brazil didn’t spend a cent on Bharat Biotech vaccine deal under probe
Politics

Bolsonaro says Brazil didn’t spend a cent on Bharat Biotech vaccine deal under probe

President Jair Bolsonaro on Thursday said Brazil never paid for or received any doses of a coronavirus vaccine developed by Indian company Bharat Biotech, in response to allegations of irregularities in a deal that is under investigation. Federal prosecutors and a special Senate committee are investigating the deal for Bharat Biotech’s Covaxin shot, citing the fact that the government struck a speedy agreement when offers from Pfizer in 2020 at a lower price were ignored at the time. “We didn’t spend one cent on Covaxin. We didn’t receive one dose of Covaxin. What sort of corruption is this?” Bolsonaro said.The president pledged to take action if any corruption was discovered in his government. Bolsonaro said the price for the Bharat vaccines was broadly in line with other ...
Covaxin phase 3 trail: Bharat Biotech’s Covaxin shows 77.8% efficacy in phase 3 trials’ | India News – Times of India
Politics

Covaxin phase 3 trail: Bharat Biotech’s Covaxin shows 77.8% efficacy in phase 3 trials’ | India News – Times of India

NEW DELHI: Bharat Biotech's Covaxin has demonstrated 77.8% efficacy in phase 3 trials, reported ANI quoting sources. The Hyderabad-based firm had earlier submitted the trial data to the Subject Expert Committee (SEC) of the Indian drug regulator. The expert panel has approved the trial data. The trials were conducted on 25,800 subjects, as per reports. Bharat Biotech's indigenously developed Covaxin is one of the three vaccines currently in use in India. Covishield, developed by AstraZeneca and manufactured locally by Serum Institute of India and Russia's Sputnik V are the other two vaccines being administered The company has developed the vaccine in association with the Indian Council of Medical Research (ICMR). Watch Covaxin phase III trial is approved by Subject Expert Committee with...
Covaxin Phase 3 Trial Data Shows 77.8% Efficacy, Gets Approval From DCGI’s Expert Panel
Politics

Covaxin Phase 3 Trial Data Shows 77.8% Efficacy, Gets Approval From DCGI’s Expert Panel

New Delhi: The result for Phase 3 clinical trial of Bharat Biotech’s Covaxin vaccine is out as the Subject Expert Committee (SEC) under India's drug regulator on Tuesday gave approval to efficacy data for the Coronavirus jab.According to the data submitted by Bharat Biotech, Covaxin has shown the efficacy of 77.8 per cent from the trial conducted on 25,800 subjects across the country, news agency ANI quoted citing sources.ALSO READ | How Effective Are Covid-19 Vaccines Against Dangerous Delta Variant Of Coronavirus?The approval was given to country's only indigenous Covid-19 vaccine after an expert panel met earlier in the day to review Covaxin's trial data.As per the procedue, SEC will not send Covaxin's Phase 3 trial data to Drugs Controller General of India (DCGI)...
Bharat Biotech has submitted Covaxin’s Phase III trial data to DCGI: Govt sources | India News – Times of India
Politics

Bharat Biotech has submitted Covaxin’s Phase III trial data to DCGI: Govt sources | India News – Times of India

NEW DELHI: The Hyderabad-based Covid vaccine manufacturing company Bharat Biotech submitted data from the Phase III clinical trials of Covaxin to Drugs Controller General of India (DCGI) over the weekend, according to government sources. "We have received the data from the phase III trials," a senior government official confirmed. Bharat Biotech's Covaxin is one of the three vaccines which are currently being used in India. The phase III data of its vaccine have been questioned various times and that is what makes the data crucial which will ascertain the efficacy of the vaccine. The company has developed the vaccine in association with the Indian Council of Medical Research (ICMR). In a press briefing a few days ago by the Union Health Ministry, Dr V K Paul, who is a member (Health) Ni...
Bharat Biotech, WHO pre-submission meeting on June 23: WHO | India News – Times of India
Politics

Bharat Biotech, WHO pre-submission meeting on June 23: WHO | India News – Times of India

NEW DELHI: Hyderabad-based Bharat Biotech's pre-submission meeting has been scheduled on June 23 for evaluation of the World Health Organisation (WHO)'s Emergency Use Listing (EUL) of its indigenous Covid-19 vaccine Covaxin. Earlier, last month, Bharat Biotech had informed that it had submitted 90 per cent of the documentation needed for WHO's EUL. The rest of the documents are to be submitted this month. The External Affairs Ministry is coordinating with Bharat Biotech to secure WHO recognition for the Covid-19 vaccine. Covaxin is among three vaccines currently being administered in India against the Covid-19 pandemic. India started the world's largest vaccination drive on January 16 this year in a phased manner with healthcare workers (HCWs) getting inoculated first. The vaccination o...
Sunanda Pushkar death case: Delhi Court adjourns to July 2 orders on framing of charges against Shashi Tharoor | India News – Times of India
Politics

Sunanda Pushkar death case: Delhi Court adjourns to July 2 orders on framing of charges against Shashi Tharoor | India News – Times of India

NEW DELHI: The Rouse Avenue Court on Wednesday adjourned the passing of the order on the issue of framing of charges in the Sunanda Pushkar death case for July 2. Shashi Tharoor, the husband of Sunanda Pushkar is the main accused in the matter according to the Delhi Police. Tharoor, former union minister, who is currently on bail in the case, was chargesheeted by Delhi Police under Sections 498-A (husband or relative of husband of a woman subjecting her to cruelty) and 306 (abetment of suicide) of the Indian Penal Code (IPC). Special Judge Geetanjali Goyal recently had kept the order reserved after prosecution and defence counsel concluded their arguments on the issue of framing of charges. Public Prosecutor stressed that Pushkar has undergone mental cruelty, which leads to her bad heal...
Ocugen selects Jubilant HollisterStier as manufacturer for Covaxin in US
Politics

Ocugen selects Jubilant HollisterStier as manufacturer for Covaxin in US

Ocugen Inc, Bharat Biotech’s US and Canada partner for its COVID-19 vaccine Covaxin, said it has chosen Jubilant HollisterStier of Spokane,Washington as its manufacturing partner for the vaccine for the North American countries. “We are fully committed to bringing Covaxin to the US and Canadian markets because we believe it has the potential to save lives by adding a weapon to the arsenal in the fight against emerging variants, J P Gabriel, Ocugen’s Senior Vice President, Manufacturing and Supply Chain said in a release on Tuesday. Bharat Biotech has entered into a definitive agreement with OcugenInc, a US-based biopharmaceutical company, to co-develop, supply, and commercialise, its Covaxin for the American and Canadian markets. The US Food and Drug Administration recently...
Bharat Biotech Defends Higher Price Of Covaxin
Politics

Bharat Biotech Defends Higher Price Of Covaxin

Hyderabad: Defending the higher price of Covaxin, Bharat Biotech on Tuesday said the supply price of the vaccine to the Centre at Rs 150 per dose is a “non-competitive price and clearly not sustainable in the long run”.Bharat Biotech said as directed by the government, less than 10% of the total production of Covaxin to date has been supplied to private hospitals, while most of the remaining quantity was supplied to the Centre and state and governments.“In such a scenario the weighted average price of COVAXIN® for all supplies realized by Bharat Biotech is less than ₹ 250 / dose. Going forward, ~75% of the capacity will be supplied to State and Central Governments with only 25% going to private hospitals,” said Bharat Biotech in a statement, adding “ hence a higher p...
Vaccines are working against infection, severe disease of Covid-19, reveals study | India News – Times of India
Politics

Vaccines are working against infection, severe disease of Covid-19, reveals study | India News – Times of India

NEW DELHI: Christian Medical College, Vellore, a 2,600 bed tertiary care hospital in India with 10,600 employees has vaccinated 84.8 per cent staff with majority of them getting Covishield and rest received Covaxin by Bharat Biotech, a latest research done on healthcare workers revealed. "Christian Medical College, Vellore, a 2,600-bed tertiary care hospital in India with 10,600 employees, vaccinated 8,991 staff (84.8 per cent) between January 21 and April 30. A majority (93.4 per cent) received Covishield, the Oxford-AstraZeneca vaccine manufactured by Serum Institute of India, and the remainder, Covaxin, a killed virus vaccine, produced by Bharat Biotech, India," said the study, "Vaccines are working against infection and severe disease of Covid-19", by CMC Vellore. Dr. Joy J Mammen, ...
No Emergency Use Approval For Covaxin In US; Phase 3 Trial Data Expected To Be Published In 7-8 Days, Says Dr VK Paul
Politics

No Emergency Use Approval For Covaxin In US; Phase 3 Trial Data Expected To Be Published In 7-8 Days, Says Dr VK Paul

New Delhi: In a significant development, the Food and Drug Administration has "recommended" Ocugen Inc, the US partner of Bharat Biotech, to go for Biologics Licence Application (BLA) route for Covaxin with additional data, nixing hopes of Emergency Use Authorisation (EUA) in the USA.Ocugen confirmed this is in a statement adding that it will pursue submission of a biologics licence application (BLA) for Covaxin. BLA is a "full approval" mechanism by the FDA for drugs and vaccines.ALSO READ | ICMR Approves Another Indigenous Covid-19 Self-Test Kit - CovidFind; Check Price & More"The company will no longer pursue an Emergency Use Authorization (EUA) for Covaxin. The FDA provided feedback to Ocugen regarding the Master File. The company had previously submitted and...